Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.

Expert opinion on pharmacotherapy - 1 Apr 2013

Pilotto Sara, Peretti Umberto, Novello Silvia, Rossi Giulio, Milella Michele, Giaj Levra Matteo, Ciuffreda Ludovica, Massari Francesco, Brunelli Matteo, Tortora Giampaolo, Bria Emilio

Abstract excerpt

INTRODUCTION: In the recent years, the growing attention to the molecular background of non-small-cell lung cancer (NSCLC) led to the identification of different molecular subtypes according to genetic abnormalities driving the disease development and progression. Whereas the addicted pathways were successfully inhibited (such as the mutant epidermal growth factor receptor), clinicians have witnessed a dramatic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Crizotinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Precision Medicine

Share to Pyrazoles

Share to Pyridines

Share to Receptor Protein-Tyrosine Kinases

Share to Translational Research, Biomedical

Source

Identifiers

PMID: 23472711
DOI: 10.1517/14656566.2013.778828

Genes

ALK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.PMID 23472711Read ↗

Treatment for ALK-mutated non-small-cell lung cancer: a new miracle in the research race.Semantic proximity Read ↗

Management of NSCLC: focus on crizotinib.Semantic proximity Read ↗

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.Semantic proximity Read ↗

Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma.Semantic proximity Read ↗

Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

ALK in lung cancer: past, present, and future.Semantic proximity Read ↗

Targeted therapy for lung cancer: Beyond EGFR and ALK.Semantic proximity Read ↗

Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer.Semantic proximity Read ↗

An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.Semantic proximity Read ↗

Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies.Semantic proximity Read ↗

Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.Semantic proximity Read ↗

Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.